BIBLIOGRAPHY FOR TOPIC 1
- de Jong JC, Palache AM,
Beyer WEP, Rimmelzwaan GF, Boon ACM, Osterhaus ADME. Haemagglutination-inhibiting antibody to
influenza virus. Developmental
Biology (Basel). 2003;115:63–73.
- Johnson
NPAS, Mueller J. Updating the accounts: Global mortality of the 1918-1920
“Spanish” influenza pandemic. Bulletin
of the History of Medicine.
2002;76:105-115.
- Reid AH, Fanning TG, Janczewski TA, Lourens RM,
Taubenberger JK. Novel origin of the 1918 pandemic influenza virus nucleoprotein
gene. Journal of Virology. 2004;78:12462-12470.
- Stephenson
I, Wood JM, Nicholson KG, Charlett A, Zambon, MC. Detection
of anti-H5 responses in human sera by HI using horse erythrocytes
following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.
Virus Research. 2004;103(1-2):91-5.
- Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G,
Fanning TG. Characterization of the
1918 influenza virus polymerase genes.
Nature. 2005;437:889-893.
- Treanor
J, et al. Safety and Immunogenicity of an Inactivated Subvirion Influenza
A (H5N1) Vaccine. The New England Journal
of Medicine. 2006; 354 (13):1343-51.
- Tumpey
TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz
JM, Taubenberger JK, Palese P, Garcia-Sastre A. Characterization of the reconstructed
1918 Spanish influenza pandemic virus.
Science. 2005;310:77-80
- Serologic
diagnosis of influenza virus by hemagglutination inhibition. In: WHO
Manual on Animal Influenza Diagnosis and Surveillance
2002.5Rev.1 Pages 37-39.
- Avian Influenza Fact
Sheet. February 2006. http://www.who.int/mediacentre/factsheets/avian_influenza
- Draft Guidance for
Industry: Toxicity Grading Scale for Healthy Adult and Adolescent
Volunteers Enrolled in Preventive Vaccine Clinical Trials.
4/9/2005.
- Draft Guidance for
Industry: Clinical Data Needed to Support the Licensure of Trivalent
Inactivated Influenza Vaccines.
3/2/2006.
- Draft Guidance for
Industry: Clinical Data Needed to Support the Licensure of Pandemic
Influenza Vaccines - 3/2/2006.